pc 버전으로 이동 중 [시장보고서]동종 CAR 특허 상황 분석(2023년)
동종 CAR 특허 상황 분석(2023년)
Allogeneic CAR Patent Landscape Analysis 2023
상품코드 : 1349507
리서치사 : KnowMade
발행일 : 2023년 09월
페이지 정보 : 영문 PDF > 120 Slides, Excel file: 416 Patent Families
EUR 4,990 ₩ 7,158,000
PDF and Excel File (Multi-user License)


한글목차

동종 CAR, 자가 CAR-T세포보다 신속하고 저가인 치료법

세포·유전자 치료 파이프라인은 임상 개발과 같이 급속히 진행되고 있습니다. FDA에 따르면 세포·유전자 치료의 IND 신청 수는 2017년으로부터 2배 초과로 증가하고 있습니다. 현재 100을 넘는 임상시험이 진행중이나, 그 수는 이 테마에 대한 높은 관심과 기업에게 경제적 이해를 반영하여 한층 더 증가하고 있습니다. 그러나 현재까지 미유럽 시장에는 아직 제품이 없으나, 주요 특허에 대한 특허 의의 제기가 이미 몇개 개시되고 있으며, 미국 기업을 중심으로 하는 몇몇 회사가 동종 CAR 분야에 신규 참여하고 있습니다.

동종 CAR 특허 상황을 조사했으며, 400개 이상 특허의 데이터베이스 및 공개 특허의 시계열 추이, 특허 출원국, 특허의 법적 현황 등의 정보를 제공하고 있습니다.

목차

서론

주요 요약

특허 상황의 개요

신규 참여 기업

제휴

주요 출원자의 IP 포지션

주요 EP 특허 의의 제기

특허 세분화

주요 기업의 IP 개요

조사 방법

KnowMade의 프레젠테이션

연락처

KSA 23.09.27
영문 목차

영문목차

Report's Key Features:

Allogeneic CAR, a faster and less expensive therapy than autologous CAR-T cells

The pipeline for cell and gene therapies has been increasing at a rapid rate as are clinical developments. According to the FDA, the number of investigational new drug applications for cell and gene therapies has more than doubled since 2017. To manage this influx, in March 2023, the Office of Therapeutic Products was established as the first super office at the FDA's Center for Biologics Evaluation and Research. Chimeric antigen receptor (CAR) cell therapies are one of the major, and perhaps, best known, components of cell and gene therapies. CAR therapies, mainly to treat cancer, are immune cells engineered to express a chimeric receptor directed against tumor antigens. Currently, there are 2 main types of CAR therapies: autologous (patient-derived) and allogeneic (from healthy donor). Allogeneic CAR are produced from third-party healthy immune cells which confers many advantages. First, allogeneic CAR treatment enables the process to be done in 10 to 11 days versus a minimum of three weeks with autologous CAR therapy. This accelerated process eliminates the need for bridging therapy therefore allowing better results. Second, a high number of CAR immune cells can be produced from a single donor enabling an industrialized manufacturing processes. Moreover, CAR products can be standardized thanks to the production of batches of cryopreserved immune cells. This industrialization also leads to a reduction of manufacturing cost and ultimately reduces the price of treatments. However, allogeneic CAR can generate graft-versus-host disease, which is life-threatening. To overcome this major problem, companies and academics develop several approaches such as the use of various immune cells (e.g., NK, macrophage), the use of induced pluripotent stem cells or umbilical cord blood as source of immune cells or gene editing tools (e.g., CRISPR, TALEN). Currently, more than 100 clinical trials are in progress, but this number increases, reflecting the interest in this topic as well as the economic stakes for companies. However, to date, there is still no product on the European and United States markets, but some patent oppositions have already been initiated against key patents, and several newcomers, mainly American, are entering the allogeneic CAR field. In this evolving context, it is crucial to understand the intellectual property position and strategy of these different players. Such knowledge can help detect business risks and opportunities, anticipate emerging technologies, and enable strategic decisions to strengthen market position.

The analysis of the time evolution of patent publications shows that interest in allogeneic CAR began in the late 2000s. However, in 2017, for the 1st time, two autologous CAR therapies have been approved by the FDA: KYMRIAH™ (tisagenlecleucel) from Novartis and YESCARTA™ (Axicabtagene Ciloleucel) from Kite Pharma, a Gilead company. These two therapies are CD19-directed genetically modified autologous T cell immunotherapies. This event allowed the CAR technology to fully develop and led to a significant increase in the number of patent families published since 2019 in allogeneic CAR area.

Analysis by segment

Allogeneic CAR have been investigated and the selected patent families labeled according to technologies to which they relate. This IP landscape features the following 4 types of segmentation: cells (T cells, NK, other), cells origin (PBMC from peripheral blood, iPSC, cord blood & placenta), gene editing tools (CRISPR, TALEN, ZFN, Meganuclease, other) and therapeutic areas (hematological malignancies , solid tumor).

EP oppositions

Currently, there is few EP oppositions which reflects the novelty of allogeneic CAR technology. Most of the proceedings are recent, having been filed in the past 5 years, and are still pending. For each opposed patent, the application date, assignee, opponent, opposition year, and results are detailed.

Identifying the companies that have recently emerged in the IP landscape

Among the players owning patent families related to allogeneic CAR, 31 newcomers were identified. These companies are either start-up firms (8) or established companies (23) developing their first technology in the field. Most IP newcomers are based in the U.S. and in Asia. It is possible that one of these innovative companies could become one of the next healthcare unicorns that the big corporations will be tempted to acquire.

IP profile of key players

This IP study includes a selection and description of main players. The patent portfolio analysis of main players includes a description of the assignee, patent portfolio description, time evolution of patent publication, main geographical coverage and live patents by technical segment. This IP profile overview is followed by the description of the technological content of their key patents and by a table with its clinical trials.

Moreover, the report also includes an Excel database with the 416 patent families analyzed in this study. This useful patent database allows for multi-criteria searches and includes patent publication numbers, hyperlinks to the original documents, priority dates, titles, abstracts, patent assignees, each patent's current legal status and segmentation.

TABLE OF CONTENTS

INTRODUCTION

EXECUTIVE SUMMARY

PATENT LANDSCAPE OVERVIEW

NEWCOMERS

COLLABORATIONS

IP POSITION OF MAIN APPLICANTS

MAIN EP PATENT OPPOSITIONS

PATENT SEGMENTATION

IP PROFILE OF KEY PLAYERS

METHODOLOGY

KNOWMADE PRESENTATION

CONTACT

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기